Lumason

(Sulfur hexafluoride lipid-type A microspheres)

Phase 3Small molecule

BBracco Diagnostics, Inc

Lumason is one of 66 small molecule programs targeting Appendicitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

AppendicitisActive, not recruiting

Necrotizing EnterocolitisActive, not recruiting

COVID-19Active, not recruiting

AppendicitisPhase 2

Active, not recruiting

Necrotizing EnterocolitisPhase 3

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Lumason

BBracco Diagnostics, Inc

Phase 3

1 2

Bnt162b2

BioNTech

Preclinical

29 3

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 4

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 5

Glucocorticoid

AbbVie

Preclinical

1 6

HB-Admscs

HHope Biosciences Research Foundation

Preclinical

4 7

Blood Taken

HHospices Civils de Lyon

Preclinical

1 8

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 9

Interferon-Gamma

SSPP Pharmaclon Ltd.

Preclinical

1 10

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Appendicitis2 trials

Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

Withdrawn·—·Phase 1·NCT03295656

The Role of Contrast Enhanced Ultrasound in Appendicitis

Completed·—·Phase 2·NCT03687502·37 enrolled

Necrotizing Enterocolitis1 trial

CEUS Evaluation of Bowel Perfusion in Necrotizing Enterocolitis

Terminated·—·Phase 3·NCT03549507·1 enrolled

Injury1 trial

CEUS Evaluation of Hypoxic Ischemic Injury

Completed·—·Phase 3·NCT03549520·1 enrolled

COVID-191 trial

Contrast Enhanced Ultrasound in COVID-19

Completed·—·Phase 3·NCT04640038·4 enrolled

Regulatory

FDA Approval Timeline[4]

Oct 15, 2014

LUMASON

NDA NDA203684

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Sulfur hexafluoride lipid-type A microspheres. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sulfur hexafluoride lipid-type A microspheres compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sulfur hexafluoride lipid-type A microspheres. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA203684). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Lumason. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Bracco Diagnostics, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBracco Diagnostics, Inc

Patent Landscape[5]

Patent Cliff

Jul 6, 2038

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10232061Jul 6, 2038

10335502Jul 6, 2038

11723869May 15, 2039

Lumason

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Appendicitis2 trials

Necrotizing Enterocolitis1 trial

Injury1 trial

COVID-191 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News